Whalegun
Lobbying

Schott Pharma USA's latest lobbying report covers Q4 2024, at $80K. Its first report covers Q2 2023; the issues it reports most are Health Issues.

Schott Pharma USA

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q2 2023
The first quarter a report named it

Lobbying by quarter

Schott Pharma USA lobbying by quarter
Schott Pharma USA lobbying by quarter
QuarterAmountReports
Q2 2023$30K1
Q3 2023$80K1
Q4 2023$80K1
Q1 2024$80K1
Q2 2024$80K1
Q3 2024$80K1
Q4 2024$80K1
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$510K · 7 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Health & Human Services, Dept of (HHS)7 reports
  • HOUSE OF REPRESENTATIVES7 reports
  • SENATE7 reports
  • Commerce, Dept of (DOC)2 reports
  • White House Office1 reports

Firms it paid

Firm
Michael Best Strategies$510K7 quarters

Former officials lobbying for it

Former position
ELIZABETH LARRABEEIntern, House of RepresentativesQ1 2024
ALEXANDER ANGELSONSpecial Assistant to the President, White House Legislative AffairsQ4 2023
BRETT EWERIntern, SenateQ4 2023
SARAH HELTONIntern, House of RepresentativesQ4 2023

Lobbying reports

Filed by
25/01/21for Q4 2024Michael Best Strategies$80K
24/10/21for Q3 2024Michael Best Strategies$80K
24/07/22for Q2 2024Michael Best Strategies$80K
24/04/22for Q1 2024Michael Best Strategies$80K
24/01/23for Q4 2023Michael Best Strategies$80K
24/01/23for Q3 2023Michael Best Strategies$80K
24/01/23for Q2 2023Michael Best Strategies$30K
24/01/22for Q2 2023Michael Best StrategiesUnder $5,000